ClinicalTrials.govrestricted
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 I
ClinicalTrials.gov study NCT00002079. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8